Over the last two decades there has been an explosion in the number of treatments available for relapsing remitting MS (RRMS), but unfortunately, there have not been the same advancements for progressive MS. To address this, MS organisations from around the world, including MS Research Australia, have banded together to form the International Progressive MS Alliance with the sole purpose of accelerating treatments options for people with progressive MS.
Barriers for clinical trials in progressive MS
One of the hurdles in developing treatments for progressive MS is the lack of a reliable and easy way to measure progression, or in other words a suitable way to measure whether any potential medication is working or not. Clinical trials involving people with relapsing MS often rely on counting relapses or MRI-detected lesions to track disease activity. However, progression is less easily measured, and usually happens over longer periods of time. This makes it hard to quickly detect whether a therapy is slowing or stopping progression in clinical trials. This is a serious roadblock for developing therapies for progressive MS.
Having objective indicators that detect progression, measure treatment impact, and predict an individual’s course and response to therapy would speed the development of new therapies and improve care for people with progressive MS. One potential measure is a biomarker call “neurofilament light” (NfL). Biomarker is short for biological marker, which is any measurable indicator of a biological process. In this context we need a biomarker of disease progression which can be readily measured, for example from a blood test.
Neurofilaments are proteins found in nerve fibres that are necessary for the proper conduction of electrical impulses by nerves. NfL is a fragment of the neurofilament protein and it enters the spinal fluid and blood when nerves are damaged by MS or other causes. Recent technological advances means that we can now detect NfL in the blood (serum and plasma), and not just in spinal fluid obtained by lumbar puncture, making it much more convenient and practical as a potential biomarker.
Studies of NfL in serum, plasma and spinal fluid have been underway to better define how this biomarker could be used to help detect and predict disease activity, progression, and response to treatments, not only in MS but in other neurological disorders. NfL is also detected in healthy individuals, and increases with age, so it is important to understand what is normal and what is not.
The international panel has now published a paper in the scientific journal Neurology that summarises what is known about NfL as a potential biomarker. They have also made recommendations for further research to refine the potential of NfL to predict disease course and detect response to therapy in progressive MS.
If NfL proves to be a reliable biomarker, this would revolutionise clinical trials in progressive MS. The International Progressive Multiple Sclerosis Alliance and its partners, including MS Research Australia, will continue to advance these initiatives to support their goal of speeding the development of therapies for the progressive forms of MS.